Earnings Anticipation: Recent chatter on X about Exact Sciences Corporation (EXAS) has focused on the upcoming quarterly earnings report expected after market close on November 3rd. Many are speculating on whether the company will meet revenue projections of over $826 million. There’s a mix of cautious hope and concern about the reported earnings per share forecasted at a loss of $0.07.
Clinical Data Buzz: Discussions on X also highlight excitement around new clinical data for colorectal cancer screening recently announced by Exact Sciences. Some users see this as a potential catalyst for stock movement, with a slight uptick in premarket interest noted. The focus remains on whether this development can drive long-term growth for the company.
Note: This discussion summary was generated from an AI condensation of post data.
Exact Sciences Corporation Insider Trading Activity
Exact Sciences Corporation insiders have traded $EXAS stock on the open market 5 times in the past 6 months. Of those trades, 0 have been purchases and 5 have been sales.
Here’s a breakdown of recent trading of $EXAS stock by insiders over the last 6 months:
- KATHERINE S ZANOTTI has made 0 purchases and 2 sales selling 15,207 shares for an estimated $950,612.
- JAMES EDWARD DOYLE has made 0 purchases and 2 sales selling 3,485 shares for an estimated $182,399.
- JAMES HERRIOTT (SVP, General Counsel & Sec) sold 1,500 shares for an estimated $90,000
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Exact Sciences Corporation Hedge Fund Activity
We have seen 260 institutional investors add shares of Exact Sciences Corporation stock to their portfolio, and 281 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PRICE T ROWE ASSOCIATES INC /MD/ removed 2,700,607 shares (-42.2%) from their portfolio in Q2 2025, for an estimated $143,510,255
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 2,596,623 shares (-89.0%) from their portfolio in Q2 2025, for an estimated $137,984,546
- GOLDMAN SACHS GROUP INC added 1,486,137 shares (+204.1%) to their portfolio in Q2 2025, for an estimated $78,973,320
- HOLOCENE ADVISORS, LP added 1,404,086 shares (+189.5%) to their portfolio in Q2 2025, for an estimated $74,613,130
- BLACKROCK, INC. removed 1,388,121 shares (-11.6%) from their portfolio in Q2 2025, for an estimated $73,764,749
- STATE STREET CORP removed 1,234,872 shares (-18.7%) from their portfolio in Q2 2025, for an estimated $65,621,098
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 1,219,545 shares (-39.0%) from their portfolio in Q2 2025, for an estimated $64,806,621
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Exact Sciences Corporation Government Contracts
We have seen $592,152 of award payments to $EXAS over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- TESTING SERVICES FOR PATIENT CARE: $323,800
- ONCOTYPE CANCER TESTING - OY 5 POP: 16 MARCH 2025 TO 15 MARCH 2026: $124,588
- ONCOTYPE GENETIC TESTING SERVICES: $114,305
- GENETIC TESTING PREVENTIONGENETICS LLC:1126164 [25-010421]: $29,459
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
Exact Sciences Corporation Analyst Ratings
Wall Street analysts have issued reports on $EXAS in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- BTIG issued a "Buy" rating on 10/22/2025
- Piper Sandler issued a "Overweight" rating on 10/08/2025
- Evercore ISI Group issued a "Outperform" rating on 10/07/2025
- Barclays issued a "Overweight" rating on 10/02/2025
- Craig-Hallum issued a "Buy" rating on 09/11/2025
To track analyst ratings and price targets for Exact Sciences Corporation, check out Quiver Quantitative's $EXAS forecast page.
Exact Sciences Corporation Price Targets
Multiple analysts have issued price targets for $EXAS recently. We have seen 7 analysts offer price targets for $EXAS in the last 6 months, with a median target of $68.0.
Here are some recent targets:
- Mark Massaro from BTIG set a target price of $75.0 on 10/22/2025
- David Westenberg from Piper Sandler set a target price of $70.0 on 10/08/2025
- Vijay Kumar from Evercore ISI Group set a target price of $68.0 on 10/07/2025
- Luke Sergott from Barclays set a target price of $65.0 on 10/02/2025
- Alex Nowark from Craig-Hallum set a target price of $85.0 on 09/11/2025
- Dan Leonard from UBS set a target price of $53.0 on 08/07/2025
- Conor McNamara from RBC Capital set a target price of $46.0 on 08/07/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
